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Most patients with refractory secondary/tertiary
hyperparathyroidism have monoclonal parathyroid tumors.
Inactivating mutations of CDKN1B, encoding the p27
cyclin-dependent kinase inhibitor, were reported to cause
hyperparathyroidism in a multiple endocrine neoplasia type
1-like syndrome. Further, there was decreased expression of
CDKN1B in parathyroid tumors of patients with chronic
kidney disease. We sequenced the entire coding region and
splice sites of CDKN1B in 50 parathyroid tumors from 35
patients to see if inactivating mutations could cause
monoclonal tumorigenesis in refractory secondary/tertiary
hyperparathyroidism. No frameshift, nonsense, or other
clearly inactivating mutations were found, nor was there
evidence of homozygous deletion or loss of heterozygosity.
The absence of clonal inactivating mutations suggests that
CDKN1B is not a classical tumor-suppressor gene in
secondary/tertiary parathyroid tumors.
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In secondary hyperparathyroidism, chronic stimulation of
the parathyroid glands typically results in multi-gland
hyperplasia. Some patients, usually after years of dialysis,
develop refractory hyperparathyroidism in which excessive
parathyroid hormone secretion no longer responds to
physiologic influences or standard medical treatments.1–3
Moreover, some patients develop irreversible hypercalcemia
in the absence of calcium or vitamin D supplementation, and
are said to have tertiary hyperparathyroidism. Medically
refractory secondary or tertiary hyperparathyroidism, which
require parathyroidectomy, are thus very different entities
from typical secondary hyperparathyroidism. Importantly,
development of monoclonal parathyroid expansions is
common in the majority of patients undergoing parathy-
roidectomy for medically refractory secondary or tertiary
hyperparathyroidism,1,4 and such monoclonal neoplasia may
be a key determinant of the medically refractory state.
However, little is known about the specific acquired genetic
abnormalities that are responsible for the selective advantage
underlying these clonal expansions.
An excellent candidate gene for which acquired mutation
could drive monoclonal hyperparathyroidism in chronic
kidney disease (CKD) patients is CDKN1B, which encodes
the p27 (or p27Kip1) cyclin-dependent kinase inhibitor. p27
serves to repress the function of cyclin-dependent kinases
that are necessary for cellular progression through G1 and
into the S phase of the cell cycle.5,6 CDKN1B contains three
exons, which form a 2.4-kb transcript that is translated to a
198-amino-acid protein. p27 protein expression has been
shown to be decreased in various tumor types, including
colon cancer.7 Recently, mutation in CDKN1B was found to
cause hyperparathyroidism in the context of MENX, a novel
multiple endocrine neoplasia syndrome observed in rats.8,9
Furthermore, CDKN1B mutation was linked to parathyroid
disease in humans, specifically in a family with a proband
who presented with an MEN1-like phenotype of pituitary
adenoma and primary hyperparathyroidism, with negative
testing for MEN1 gene mutation.8 It is plausible that the
effects of p27 deficiency could be similar to MEN1
inactivation, since the MEN1 gene product menin has been
reported to complex with histone H3 lysine 4, and act as a
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methylation complex necessary for proper p27 activity.10
Additionally, parathyroid glands from patients with second-
ary hyperplasia show less CDKN1B expression than normal
controls;11 moreover, those glands showing nodular hyper-
plasia displayed significantly less p27 staining than those with
diffuse secondary hyperplasia.11–13 The involvement of p27 in
endocrine neoplasia, specifically in parathyroid disease, and
its decreased expression in renal failure-associated parathy-
roid tumors, raises the hypothesis that CDKN1B may be
subject to acquired somatic mutation with loss of function,
thus serving as a tumor-suppressor gene in monoclonal
secondary or tertiary hyperparathyroidism.
While the term ‘tumor suppressor’ is often loosely used,
the fundamental and most rigorous definition is that of
‘genes that sustain loss-of-function mutations’ in the
development of tumors.14 This crucial importance of
demonstrating mutations, as opposed to expression abnorm-
alities, derives from their clonality, which serves as functional
evidence that the mutation conferred a selective advantage in
an original tumor progenitor cell. Thus, while genes can be
under-expressed in tumors for many reasons, for example, as
a result of rapid cellular growth or downstream of true
drivers of tumorigenesis, only recurrent inactivating muta-
tions provide the crucial evidence for a gene’s primary
driving role in tumor development and thereby define it as a
tumor suppressor. In this study, we sought such mutational
evidence for CDKN1B.
RESULTS
We analyzed DNA from the parathyroid tumors of patients
with severe secondary or tertiary hyperparathyroidism for
intragenic mutations within the coding region of CDKN1B,
because clonal inactivating mutations provide the most
crucial and definitive evidence that a gene serves as a tumor
suppressor. No point mutations, insertions, or deletions that
would be expected to inactivate the p27 gene product were
identified. Furthermore, the two coding exons of CDKN1B
were readily amplified by polymerase chain reaction (PCR) in
all samples, indicating that homozygous deletion of the gene
had not occurred. Heterozygosity for the common V109G
polymorphism was present in 7 of the 35 patients, which is
approximately in agreement with the predicted heterozygote
frequency of 0.3 (http://www.hapmap.org), providing
evidence that loss of heterozygosity was not a major feature
at this locus. This observation is reinforced by the absence of
copy number alterations found on the 12p chromosomal arm
(the location of CDKN1B) in previous studies using
microsatellite analysis and comparative genomic hybridiza-
tion in 33 of these 50 tumors.4
CDKN1B contains many known polymorphisms, three
of which were present in our set of samples15–18 (http://
genome.ucsc.edu). The V109G polymorphism, noted above,
was present in tumors from 10 patients, with homozygosity
for the variant present in samples from three patients,
consistent with its reported high prevalence in the popula-
tion.15–17 Next, one patient’s samples had a T-to-C transition
at codon 119 in exon 1, changing the encoded amino acid
from Ile to Thr. This patient had two glands analyzed and the
change was found on one allele in each gland, with the
second allele retaining the wild-type sequence. Matched
normal control DNA from this individual was unavailable for
sequencing, but the presence of precisely the same change in
two independent tumors strongly suggests that it was a
germline alteration in agreement with its reported prevalence
of 0.6% as a rare polymorphism in a population with
hereditary prostate cancer.18
The final CDKN1B alteration uncovered was a G-to-A
change at the third position of codon 142, conserving the
encoded amino acid Thr. This germline heterozygous change
was found in one patient’s tumor and leukocyte DNA.
Interestingly, the identical germline change was found in 1 of
34 patients with familial hyperparathyroidism and an MEN1-
like phenotype without MEN1 mutation,19 but has otherwise
only been reported in 1 of 36 breast carcinomas.17 This
alteration was not found in numerous other studies, which
collectively sequenced CDKN1B in over 450 samples,15,16,18,20
raising the possibility that it might be a rare hyperparathy-
roid-predisposition allele enriched in the disease population.
Aside from these alterations, no other variations from the
published normal CDKN1B sequence were present in any of
the samples studied.
DISCUSSION
CDKN1B, the gene encoding the cyclin-dependent kinase
inhibitor p27Kip1, has recently been identified as a tumor-
suppressor gene whose mutational inactivation caused
hyperparathyroidism in the context of a multiple endocrine
neoplasia disorder.8 This finding, in conjunction with
decreased p27 expression in secondary parathyroid tumors
has established CDKN1B as an important candidate gene,
which could contribute to parathyroid tumorigenesis
through inactivating somatic mutation.11–13 We have
sequenced the entire coding region of CDKN1B, plus splice
sites, and found no clonal somatic mutations. Since
inactivating mutations are the central and crucial element
in defining classical tumor-suppressor genes, we have used
direct sequencing to address the central criterion that would
allow CDKN1B to be classified as a tumor suppressor gene in
these parathyroid tumors. Our sequencing approach would
not have detected mutations in introns, the promoter region,
or the untranslated regions, but on the basis of the knowledge
of other classical tumor suppressors, it would be unprece-
dented if inactivating mutations were to occur solely in these
locations to the complete exclusion of coding mutations.
Thus, the absence of detectable somatic mutations in our
study makes it exceedingly unlikely that acquired CDKN1B-
inactivating mutation is a primary contributor to mono-
clonal growth, or to decreased p27 protein expression, in
severe secondary and tertiary parathyroid tumors.
The three alterations we observed in CDKN1B are
previously reported germline polymorphisms.15–18 We found
the rare T142T polymorphism in one patient in the study
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population, and it was also found recently in a patient with
multiple parathyroid tumors and familial disease, which
resembled MEN1.19 While it is unlikely that this alteration
would lead to a decrease in cellular p27 protein, the
possibility that it could affect gene expression and predispose
to hyperparathyroidism cannot be excluded.
While our observations strongly suggest that CDKN1B
inactivation is not an important primary driver of clonal
parathyroid growth in CKD patients, one cannot rule out the
possibility that the decreased p27 staining previously found
in many parathyroid tumors might participate in parathyroid
tumorigenesis in a secondary manner. Additionally, 1,25-
dihydroxyvitamin D3 (1,25(OH2)D3) has been shown to
decrease the activity of cyclin E–CDK2 proteins, as well as
decrease amounts of Skp2, which act to target p27 for
ubiquitination and degradation.21 Therefore, increased
1,25(OH2)D3 action on the cell could augment p27 levels
and suppress cellular growth. Conversely, the low levels
of 1,25(OH2)D3 characteristic of severe CKD could lead to
increased p27 degradation and lower p27 levels. An
association between decreased p27 levels and decreased
vitamin D receptor levels has also been illustrated in nodular
parathyroid tumors from uremic patients.12,13 The mecha-
nism underlying decreased vitamin D receptor quantity,
which may contribute to decreased p27 levels, has not yet
been elucidated; mutational analysis of vitamin D receptor in
secondary parathyroid tumors has revealed no mutations.22
Thus, further studies are needed to clarify the mechanisms by
which clonal growth occurs in severe secondary and tertiary
hyperparathyroidism.
MATERIALS AND METHODS
Patients and samples
We studied 50 resected parathyroid tumors from 35 patients with
CKD and refractory secondary or tertiary hyperparathyroidism. The
mean age of these patients (data available for 33/35 patients) was 44
years, (range 16–68). All patients were undergoing treatment
with maintenance hemodialysis. Parathyroidectomy was indicated
because of severe secondary hyperparathyroidism associated with
pruritus, osteitis fibrosa, soft tissue calcification, hyperphosphatemia,
and/or other symptoms and signs, which were resistant to medical
treatment. It is crucial to emphasize that the patients in our study
with ‘secondary’ hyperparathyroidism were not representative of
common secondary hyperparathyroidism, which would be expected
to exhibit a generalized polyclonal hyperplasia of the parathyroids;
instead, the fact that our patients required parathyroidectomy puts
them in the special category of hyperparathyroidism refractory to
medical therapies. In no case was CKD a consequence of primary
hyperparathyroidism. The mean serum calcium level was 10.6 mg
per 100 ml (data available for 31/35 patients) and serum parathyroid
hormone levels were markedly elevated (average 17-fold above the
upper limit of normal) (data available for 30/35 patients). No
patient had a family history of hyperparathyroidism or multiple
endocrine neoplasia, or a history of head and neck irradiation. In all
patients, multiple hypercellular parathyroid tumors were identified
and resected. The number of glands excised by the surgeon for each
patient was not always known, but the surgeons’ usual practice was
to perform a X3.5 gland resection; in general, when portions of
only one or two of the resected glands were made available to us for
study, these tended to be from the largest gland(s). In other words,
this represented selection by the pathologist rather than a limited
resection by the surgeon. Importantly, glands obtained in exactly the
same manner as these have been frequently demonstrated to be
monoclonal, including fully 19 of the glands in this study which
were part of a previous clonal analysis by X-chromosome
inactivation.1 One parathyroid gland was available for study from
24 patients; two glands were available from each of eight patients;
three glands were available from one patient; and four glands were
available from each of two patients. Peripheral blood leukocytes,
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Figure 1 | CDKN1B amplification and sequencing strategy. (a) Schematic diagram of the PCR amplification of the coding regions and splice
sites of CDKN1B. The untranslated region is represented by hashed markings. (b) Fragments produced are depicted with their primers and
corresponding lengths. Annealing temperatures are as follows for each primer pair: 1AF–1BR, 61 1C; 1AF–1AR, 551C; 1BF–1BR, 55 1C; 1CF–1CR,
61 1C; and 2F–2R, 55 1C.
Table 1 | Primers used for both PCR amplification and
sequencing of the coding regions and splice sites of CDKN1B
Primer name Sequence
1AF 50-GGCGCTTTGTTTTGTTCGGTT-30
1AR 50-GTCCCGGGTTAACTCTTCGTG-30
1BF 50-CCCTAGCCTGGAGCGGATGG-30
1BR 50-GGAGCCCCAATTAAAGG-30
1CF 50-ATTTTCAGAATCACAAACCC-30
1CR 50-AAGCAGTGGGCCAGGTAGCAC-30
2F 50-GTTTTTCATCCCCTGACTAT-30
2R 50-AATTTGCCAGCAACCAGTAAG-30
PCR, polymerase chain reaction.
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providing matched control non-tumor DNA, were available from 25
patients. All tissue and blood specimens were obtained in
accordance with the University of Connecticut institutional review
board-approved protocol no. 00-089.
Surgical samples were grossly dissected and quickly frozen in
liquid nitrogen. Parathyroid specimens were frozen in liquid
nitrogen after surgical removal and stored at 80 1C. High-
molecular-weight genomic DNA was extracted from frozen tissue
using standard procedures, including proteinase K digestion,
phenol–chloroform extraction, and ethanol precipitation. Leukocyte
DNA was extracted using standard procedures.23
CDKN1B sequencing
The entire coding region, consisting of two exons and splice sites of
the CDKN1B gene, was amplified by PCR from the DNA of 50
resected tumors (Figure 1) and, as described below, in one patient’s
matched leukocyte DNA sample to evaluate an apparent poly-
morphism. Exon 1 was amplified as four overlapping fragments,
with primers listed in Table 1. The following primers were paired
together: 1AF and 1BR; 1CF and 1CR. Some samples required that
the first fragment be split further into two fragments to achieve
adequate PCR amplification. Primer 1AF was paired with 1AR and
1BF was paired with 1BR. CDKN1B exon 2 was amplified to form
one single PCR product with primers 2F and 2R. PCR reactions
were performed in 20-ml reaction volumes containing 25 ng genomic
DNA, 20 pmol of each primer, 200mM of each dNTP, 1.25 U of
Amplitaq Gold DNA Polymerase (Applied Biosystems, Foster City,
CA, USA), and 2 mM magnesium chloride. Thermocycling consisted
of an initial denaturation step of 95 1C for 10 min; 35 cycles of 95 1C
for 30 s, the optimized Ta (Figure 1) for 30 s, 72 1C for 30 s; and a
final extension step at 72 1C for 10 min. PCR products were purified
using EXOSAP 10 U exonuclease I and 1 U Shrimp alkaline
phosphatase (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). Purified PCR fragments were then sequenced in both forward
and reverse directions using the Dye Terminator Cycle Sequencing
Quick Start kit (Beckman-Coulter, Fullerton, CA, USA) with the
same primers used for PCR, under conditions recommended by the
manufacturer. The resulting sequence fragments were purified
through Sephadex G-50 columns (Sigma Aldrich, St Louis, MO,
USA) and electrophoresed on a CEQ 8800 Genetic Analysis System
(Beckman-Coulter). Some samples, particularly those of exon 1,
were confirmed by sequencing performed by Genewiz Inc (North
Brunswick, NJ, USA) using Applied Biosystems Big Dye version 3.1.
The reactions were then run on the Applied Biosystems 3730xl DNA
Analyzer. Resulting sequence data were analyzed and compared with
the published sequence (RefSeq ID: NM_000315) using Sequencher
software (GeneCodes Corporation, Ann Arbor, MI, USA).
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